Insider Selling: McKesson (NYSE:MCK) EVP Sells $796,640.00 in Stock

McKesson Corporation (NYSE:MCK) EVP Francisco Fraga sold 800 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $995.80, for a total value of $796,640.00. Following the transaction, the executive vice president directly owned 5,423 shares in the company, valued at approximately $5,400,223.40. This represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

McKesson Stock Down 1.5%

Shares of NYSE:MCK opened at $1,014.79 on Thursday. The company has a market cap of $118.31 billion, a P/E ratio of 27.16, a P/E/G ratio of 2.05 and a beta of 0.30. McKesson Corporation has a 52 week low of $723.68 and a 52 week high of $1,030.27. The business has a fifty day simple moving average of $905.65 and a 200-day simple moving average of $840.38.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping the consensus estimate of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The firm had revenue of $105.38 billion for the quarter, compared to the consensus estimate of $103.88 billion. During the same period in the prior year, the business posted $8.26 earnings per share. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Sell-side analysts expect that McKesson Corporation will post 44.71 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio is currently 10.06%.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Analyst price-target increases supported the long-term outlook. UBS raised its target to $1,200, while Mizuho lifted its target to $1,020 from $905, although Mizuho maintained a neutral rating. The analyst actions followed McKesson’s recent strength and helped the stock reach a new one-year high. UBS raises target for McKesson
• Positive Sentiment: McKesson declared its regular quarterly dividend. The company will pay $0.94 per share on January 4, 2027, to shareholders of record on December 1. The dividend provides continuity for income-focused investors, though the annualized yield is modest at approximately 0.4%. McKesson declares quarterly dividend
• Neutral Sentiment: Investor attention remains elevated. McKesson was among the more-trending stocks on Zacks, but the article primarily reviews existing fundamentals rather than introducing a new catalyst. Its latest reported quarter showed earnings and revenue above estimates, with revenue up 7.7% year over year and fiscal 2027 EPS guidance of $44.20–$45.00. Is Trending Stock McKesson a Buy Now?
• Negative Sentiment: An executive sale may have added modest selling pressure. EVP Francisco Fraga sold 800 shares worth approximately $796,640. However, the transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, reducing its significance as a discretionary bearish signal. McKesson executive stock sale

Hedge Funds Weigh In On McKesson

A number of large investors have recently modified their holdings of MCK. Nvwm LLC raised its holdings in McKesson by 933.3% in the third quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 28 shares during the period. Delos Wealth Advisors LLC acquired a new position in McKesson during the second quarter valued at approximately $27,000. Trellis Wealth Advisors LLC acquired a new position in McKesson during the third quarter valued at approximately $32,000. Clearstead Trust LLC purchased a new stake in McKesson during the second quarter worth approximately $37,000. Finally, GK Wealth Management LLC purchased a new stake in McKesson during the third quarter worth approximately $38,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MCK has been the topic of several research analyst reports. Argus raised their target price on shares of McKesson from $850.00 to $970.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Citigroup upped their price target on shares of McKesson from $945.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $845.00 price target on shares of McKesson in a research note on Monday, September 14th. Mizuho increased their price target on shares of McKesson from $905.00 to $1,020.00 and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Bank of America lifted their price target on shares of McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $997.12.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.